Moderna Therapeutics, a company which is developing messenger RNA therapeutics, a new treatment modality to enable the in vivo production of therapeutic proteins, announced last week the expansion of their headquarters to Technology Square in Cambridge, Massachusetts.
With the addition of the new space, Moderna will have up to 100 full-time employees at two locations by the end of 2013.
"We are thrilled to expand our presence in Massachusetts, the country's most important hub of biotech innovation, which has been a great source of talent and ideas to Moderna from its earliest days," said Stephane Bancel, president and founding CEO of Moderna.
The new site will be the center of Moderna's R&D and provide a significant increase in laboratory space for formulation, screening, and both in-vivo and in-vitro studies.
"On behalf of the team at the Massachusetts Life Sciences Center, congratulations to Moderna on its expansion here in the Commonwealth," said The Massachusetts Life Sciences Center (MLSC) CEO Dr. Susan Windham-Bannister. "We are pleased to have awarded Moderna 2011 and 2012 Tax Incentives tied to their new job creation in Massachusetts and look forward to the great R&D efforts in 'messenger RNA Therapeutics' that will be taking place in this new space."
The MLSC is an investment agency that supports life sciences innovation, research, development and commercialization. The MLSC is charged with implementing a 10-year, $1-billion, state-funded investment initiative.
